Minted: - / 5000

2080 Panamesine
325cebbd6bca69685113d1e1ca3d1a6d038b622ff651be23449bb0fe9985be33

Properties

Background

Green
Bottle

Purple
Cap

Orange
Syringe

Purple
Bubbles
No
Drops
No
Label
Leaf

Chemistry

Formula
C23H26N2O6
Carbon
23
Polarity
Neutral

Panamesine (; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ₁ and σ₂ receptors (IC₅₀ = 6 nM). In addition, the major metabolite of the drug, EMD-59983, has high affinity for the sigma receptors (IC₅₀ = 24 nM) and the dopamine D₂ (IC₅₀ = 23 nM) and D₃ receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development.

From Wikipedia, the free encyclopedia. License: CC BY-SA.